Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Keratosis, Actinic 4Neoplasms 2Keratosis 2Stomach Neoplasms 1Precancerous Conditions 1Lymphoma 1Leukemia, Myeloid, Acute 1Carcinoma 1Breast Neoplasms 1Bone-Metastatic, Castration-Resistant Prostate Cancer 1

Interventions

Carboplatin 31Cisplatin 24pembrolizumab 23Pemetrexed 21Paclitaxel 21Gemcitabine 10osimertinib 9durvalumab 9Nivolumab 9130-nm albumin-bound paclitaxel 8Sunitinib 7Sorafenib 7Fluorouracil 7Everolimus 7Docetaxel 7Axitinib 7Cetuximab 6epothilone B 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5volociximab 4trebananib 4reolysin 4catumaxomab 4cabozantinib 4atezolizumab 4Radiotherapy 4Ipilimumab 4vosaroxin 3liposomal doxorubicin 3lenvatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma × tirbanibulin × Clear all
NCT01764087 2015-05-18

A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

Hanmi Pharmaceutical Company Limited

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinal

Breast Neoplasms, Carcinoma, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡